SubHero Banner

Arikayce® (amikacin liposome inhalation suspension) – New orphan drug approval

September 28, 2018 - The FDA announced the approval of Insmed’s Arikayce (amikacin liposome inhalation suspension) for adults, who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy.

Download PDF